by Micah Harman | Jan 8, 2025 | Press Releases, Interviews/Speaking/Events, News & Media
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel... by Micah Harman | Jan 8, 2025 | Press Releases
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs January 7, 2025 The study’s success could transform obesity treatment globally Positions the UAE as a hub for cutting-edge clinical research Abu Dhabi, UAE: To... by Micah Harman | Jan 6, 2025 | Press Releases
LEHI, Utah, Jan. 6, 2025 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, is pleased to announce key leadership additions and promotion to further its... by Micah Harman | Dec 10, 2024 | Press Releases
Treatment with HT-6184 has shown to improve hematological response in patients enrolled to date with LR-MDS, surpassing the threshold Halia advances to second stage expansion of Phase 2 trial LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a... by Micah Harman | Dec 5, 2024 | Press Releases
LEHI, Utah, Dec. 5, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for chronic inflammatory diseases, today announced that David J. Bearss, Ph.D., Co-Founder,... by Micah Harman | Oct 31, 2024 | Press Releases, Interviews/Speaking/Events
HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic... by Micah Harman | Oct 21, 2024 | Press Releases
Halia Therapeutics will showcase its LRRK2 and NEK7 inhibitors targeting Alzheimer’s disease and obesity. LEHI, Utah, Oct. 21, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative... by Micah Harman | Oct 14, 2024 | Press Releases, Interviews/Speaking/Events
Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT LEHI, Utah, Oct. 14, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage... by Micah Harman | Oct 8, 2024 | Press Releases, News & Media
LEHI, Utah, Oct. 8, 2024 /PRNewswire/ — Dr. David Bearss, CEO and Co-founder of Halia Therapeutics has been named an honoree of the 2024 PharmaVoice 100 list in the Standout Leaders category. This prestigious recognition... by Halia Therapeutics | Oct 7, 2024 | Press Releases
LEHI, Utah, Oct. 7, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that the first... by Halia Therapeutics | Sep 23, 2024 | Press Releases
LEHI, Utah, Sept. 23, 2024 — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184,... by Micah Harman | Sep 10, 2024 | Press Releases
Dr. David J. Bearss, CEO, will present data from the Phase II study evaluating the efficacy of HT-6184 on post-procedural inflammatory and pain responses on Thursday, September 12, 2024 LEHI, Utah, Sept. 10, 2024 /PRNewswire/ — Halia Therapeutics, Inc.... by Halia Therapeutics | Sep 3, 2024 | Press Releases
LEHI, Utah , Sept. 3, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced a pivotal... by Micah Harman | Aug 6, 2024 | Press Releases
Lehi, UT, August 6th, 2024/PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company, today announced that Dr. David J. Bearss, President and CEO, and a renowned drug developer, will be giving an oral presentation highlighting the company’s latest... by Micah Harman | Jul 31, 2024 | Press Releases
LEHI, Utah, July 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, and Biolexis Therapeutics, a biotechnology company... by Micah Harman | Jul 23, 2024 | Press Releases
David J. Bearss, PhD channels years of expertise to his work with Halia and Biolexis Therapeutics ALPINE, UT, July 19, 2024 /24-7PressRelease/ — David J. Bearss, PhD has been included in Marquis Who’s Who. As in all Marquis Who’s Who biographical... by Micah Harman | Jun 13, 2024 | Press Releases
NEWS PROVIDED BY Venture Capital PodcastJun 13, 2024, 00:35 ET — The 2024 list celebrates the top 100 founders driving innovation and growth in the Utah community — LEHI, Utah, June 13, 2024 /PRNewswire/ — Today, the Venture...
by Micah Harman | May 29, 2024 | Press Releases
Preliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 inMDS patients will be presented at the EHA 2024 Hybrid Congress. LEHI, Utah, May 29, 2024 /PRNewswire/... by Micah Harman | May 14, 2024 | Press Releases
CEO Dave Bearss, Ph.D., will be participating in a panel discussing the “Landscape of Drug Discovery and Impact of AI Discussion” on Wednesday, May 22, from 1:50 to 2:30 p.m. CEST Company presentation to unveil new data from HT-4253 in its new clinical...
by Micah Harman | Apr 17, 2024 | Press Releases
*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat...